Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children

Abstract EN

Applications of the heptavalent pneumococcal conjugate vaccine (PCV7) in the pediatric immunization schedule have dramatically reduced the incidence of pneumococcal diseases in both vaccinated children and unvaccinated individuals of all ages.

However, increased infections caused by non-PCV7 serotypes have been reported by several groups.

To overcome this problem, new vaccines covering more serotypes including the emerging serotypes have been developed.

The 13-valent pneumococcal conjugate vaccine (PCV13) currently covers the 7 PCV7 serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional serotypes 1, 3, 5, 6A, 7F, and 19A.

After the first year of PCV13 applications in the immunization schedule in young children, global evaluation studies demonstrated that PCV13 provided a wider coverage and more effective prevention than PCV7 against invasive pneumococcal diseases (IPDs), mucosal pneumococcal diseases, and pneumococcal carriage.

We reviewed the effects of PCV13 in the control of pneumococcal diseases in children based on previous studies.